Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07470840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 6 entries
  2. Eligibility criteria revisedv3
  3. Secondary endpoints: details revised at 1 of 6 entries
    • Study title expanded, about 7 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
Trial Details
NCT Number NCT07470840
Lead Sponsor Fujian Cancer Hospital
Conditions
(from sponsor)		 Locally Advanced or Metastatic Renal Cell Carcinoma
Related terms Carcinoma, Renal Cell
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov